Get the Stockscreener App
20.69
11.90%
2.20
After Hours:
20.57
-0.12
-0.58%
Summit Therapeutics Inc stock is traded at $20.69, with a volume of 2.80M.
It is up +11.90% in the last 24 hours and down -3.77% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$18.49
Open:
$18.74
24h Volume:
2.80M
Relative Volume:
1.22
Market Cap:
$15.26B
Revenue:
$956.00K
Net Income/Loss:
$-196.68M
P/E Ratio:
-86.21
EPS:
-0.24
Net Cash Flow:
$-113.02M
1W Performance:
-6.46%
1M Performance:
-3.77%
6M Performance:
+59.40%
1Y Performance:
+355.73%
1-Day Range:
$18.50
$20.77
1-Week Range:
$17.70
$22.71
52-Week Range:
$2.10
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
20.69 | 15.26B | 956.00K | -196.68M | -113.02M | -0.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 123.21B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 31.94B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.00B | 3.32B | -860.46M | -1.04B | -8.32 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at The Goldman Sachs Group - MarketBeat
Equities Analysts Offer Predictions for SMMT Q1 Earnings - MarketBeat
Summit Therapeutics' (SMMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Goldman Sachs Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation - MSN
StockNews.com Downgrades Summit Therapeutics (NASDAQ:SMMT) to Sell - MarketBeat
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Summit Therapeutics Stock Surges Amid Promising Trials - TipRanks
Goldman Sachs Initiates Summit Therapeutics at Buy With $42 Price Target -February 28, 2025 at 08:12 am EST - Marketscreener.com
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 15.6%Time to Sell? - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Releases Quarterly Earnings Results, Hits Expectations - MarketBeat
Brokerages Set Summit Therapeutics Inc. (NASDAQ:SMMT) Price Target at $33.57 - MarketBeat
Summit Therapeutics's Options Frenzy: What You Need to Know - Benzinga
Summit Therapeutics Inc. (SMMT): Among the Stocks That Will Go to the Moon According to Analysts - MSN
Summit Therapeutics (NASDAQ:SMMT) Issues Earnings Results, Hits Estimates - MarketBeat
Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown - MSN
Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2024 Earnings Call Transcript - MSN
Why Summit Therapeutics Inc. (SMMT) Went Down On Monday? - Insider Monkey
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer - MSN
Positive Outlook for Summit Therapeutics: Strategic Collaborations and Promising Trials Justify Buy Rating - TipRanks
Summit inks ADCs deal with Pfizer - The Pharma Letter
Summit Therapeutics Inc (SMMT) Q4 2024 Earnings Call Highlights: - GuruFocus.com
Buy Rating for Summit Therapeutics Driven by Strategic Pfizer Collaboration and Promising Clinical Trial Readouts - TipRanks
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus.com
Summit Therapeutics Inc (SMMT) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... - Yahoo Finance
Summit Therapeutics: Strong Financials and Strategic Collaborations Drive Buy Rating - TipRanks
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs - Lelezard
15 Stocks That Will Go to The Moon According to Analysts - Insider Monkey
Summit Therapeutics Reports 2024 Financials and Progress - TipRanks
Summit Therapeutics Highlights Q4 Results and FDA Fast Track - TipRanks
Can This Summit-Pfizer Cancer Drug Combo Revolutionize Solid Tumor Treatment? - StockTitan
SMMTSummit Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Earnings call transcript: Summit Therapeutics Q4 2024 sees stock drop 13.6% - Investing.com Australia
U.S. Markets Closed Mixed Monday As Sun Communities Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program (SMMT) - Seeking Alpha
Stifel maintains Summit Therapeutics at Hold with $40 target - Investing.com
Stifel maintains Summit Therapeutics at Hold with $40 target By Investing.com - Investing.com South Africa
Summit Therapeutics falls on wider Q4 loss, deal expectations from investors - TradingView
Stifel Reiterates Hold Rating on Summit Therapeutics plc (SMMT) - StreetInsider.com
Summit Therapeutics announces clinical trial collaboration with Pfizer - MSN
Summit Therapeutics advances ivonescimab with Pfizer collaboration and expanded trials - MSN
Is Summit Therapeutics (SMMT) One of the Best Growth Stocks to Invest In According to Analysts? - Insider Monkey
Summit Therapeutics Shares Fall as Q4 Net Loss Widens -February 24, 2025 at 11:34 am EST - Marketscreener.com
Pfizer: What The Summit Therapeutics Deal Brings (NYSE:PFE) - Seeking Alpha
Summit Therapeutics Stock Sinks as Firm Reports Widening Loss - MSN
Pfizer: collaboration agreement with Summit Therapeutics -February 24, 2025 at 09:56 am EST - Marketscreener.com
Summit Therapeutics shares rise on Pfizer trial collaboration By Investing.com - Investing.com South Africa
Summit Therapeutics shares rise on Pfizer trial collaboration - Investing.com
Summit Therapeutics (SMMT) Announces Clinical Trial Collaboration with Pfizer (PFE) to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs) - StreetInsider.com
Summit Therapeutics stock soars over 8 % after Q4 earnings beat - Investing.com India
Summit Therapeutics stock soars over 8 % after Q4 earnings beat By Investing.com - Investing.com Australia
Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos -February 24, 2025 at 07:00 am EST - Marketscreener.com
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Summit Therapeutics Inc Stock (SMMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zanganeh Mahkam | Chief Executive Officer |
Mar 26 '24 |
Buy |
3.75 |
30,000 |
112,500 |
30,000 |
| Zanganeh Mahkam | Chief Executive Officer |
Mar 27 '24 |
Buy |
3.72 |
26,000 |
96,720 |
520,814 |
| Dhingra Ankur | Chief Financial Officer |
Mar 26 '24 |
Buy |
3.75 |
100,000 |
375,000 |
354,958 |
3.16%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):